According to Emergent BioSolutions 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.15894. At the end of 2022 the company had a P/E ratio of -2.64.
Year | P/E ratio | Change |
---|---|---|
2022 | -2.64 | -126.26% |
2021 | 10.0 | -35.24% |
2020 | 15.5 | -69.54% |
2019 | 50.9 | 7.32% |
2018 | 47.4 | 99% |
2017 | 23.8 | -16.55% |
2016 | 28.6 | 13.48% |
2015 | 25.2 | -11.29% |
2014 | 28.4 | 6.11% |
2013 | 26.7 | 8.33% |
2012 | 24.7 | -6.22% |
2011 | 26.3 | 82.82% |
2010 | 14.4 | 8.02% |
2009 | 13.3 | -64.79% |
2008 | 37.8 | 490.79% |
2007 | 6.41 | -29.41% |
2006 | 9.07 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 13.7 | -8,688.46% | ๐บ๐ธ USA |
Merck MRK | 72.0 | -45,410.12% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 11.8 | -7,500.21% | ๐ฌ๐ง UK |
Soligenix SNGX | -0.1592 | 0.16% | ๐บ๐ธ USA |
SIGA Technologies SIGA | 23.1 | -14,637.12% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | -15.1 | 9,416.17% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | -6.91 | 4,244.41% | ๐ฎ๐ฑ Israel |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.